As much as 30% of healthcare costs in the United States can be attributed to fraud, waste, and abuse, according to a 2019 article in the Journal of the American Medical Association. IngenioRx’s 2020 Drug Trend Report examined two of the most common wasteful practices — drug re-labeling and medical device classification — as well as the pharmacy benefit manager’s successful response. Last year, IngenioRx saved clients $13 million by reducing and preventing wasteful claims. A new article on Ingenio-rx.com looks at the expertise of the pharmacy benefit manager’s fraud, waste, and abuse teams. The article shows how wasteful practices can target vulnerable populations, and the ways IngenioRx denies these claims, reduces wasteful spending, and improves members’ whole health. Download the PDF version of the article to share with your clients.